| Literature DB >> 34287355 |
Eftychia Pappa1, Konstantinos Vougas2, Jerome Zoidakis2, William Papaioannou3, Christos Rahiotis1, Heleni Vastardis4.
Abstract
Saliva, an essential oral secretion involved in protecting the oral cavity's hard and soft tissues, is readily available and straightforward to collect. Recent studies have analyzed the salivary proteome in children and adolescents with extensive carious lesions to identify diagnostic and prognostic biomarkers. The current study aimed to investigate saliva's diagnostic ability through proteomics to detect the potential differential expression of proteins specific for the occurrence of carious lesions. For this study, we performed bioinformatics and functional analysis of proteomic datasets, previously examined by our group, from samples of adolescents with regulated and unregulated type 1 diabetes, as they compare with healthy controls. Among the differentially expressed proteins relevant to caries pathology, alpha-amylase 2B, beta-defensin 4A, BPI fold containing family B member 2, protein S100-A7, mucin 5B, statherin, salivary proline-rich protein 2, and interleukin 36 gamma were significantly downregulated in poorly-controlled patients compared to healthy subjects. In addition, significant biological pathways (defense response to the bacterium, beta-defensin activity, proline-rich protein activity, oxygen binding, calcium binding, and glycosylation) were deregulated in this comparison, highlighting specific molecular characteristics in the cariogenic process. This analysis contributes to a better understanding of the mechanisms involved in caries vulnerability in adolescents with unregulated diabetes.Entities:
Keywords: bioinformatics; caries; diabetes; proteome; proteomics; saliva
Year: 2021 PMID: 34287355 PMCID: PMC8293329 DOI: 10.3390/proteomes9030033
Source DB: PubMed Journal: Proteomes ISSN: 2227-7382
Clinical characteristics and caries index (DMFT) of the study population (* p-value < 0.05). Mean and standard deviation values (means ± SD) are reported.
| Participants’ Characteristics | G1 | G2 | C |
|---|---|---|---|
| Age (yrs), mean (SD) | 14.5 ± 1.7 | 14.1 ± 1.3 | 14.9 ± 1.8 |
| Gender, | 5/7 | 5/7 | 5/7 |
| Time with DM1 (yrs) | 5.8 ± 1.9 | 6.4 ± 2.8 | - |
| HbA1c% (mmol/mol) | 9.7 ± 0.7 * (83) | 6.2 ± 0.4 * (44) | 4.2 ± 0.4 * (22) |
| BMI (kg/m2) | 22.9 ± 4.0 | 20.7 ± 5.0 | 24.3 ± 3.0 |
| Blood Pressure (mmHg) | 82 ± 5 | 79 ± 4 | 85 ± 5 |
| Diastolic Blood Pressure (mmHg) | 67 ± 3 | 63 ± 3 | 70 ± 4 |
| Systolic Blood Pressure (mmHg) | 113 ± 4 | 109 ± 3 | 114 ± 3 |
| Total cholesterol (mg/dL) | 165 ± 10 | 160 ± 12 | 168 ± 15 |
| LDL cholesterol (mg/dL) | 92 ± 6 | 88 ± 5 | 94 ± 8 |
| Plaque Index (PI) | 0.80 ± 0.05 | 0.60 ± 0.03 | 0.70 ± 0.02 |
| Gingival Index (GI) | 0.7 ± 0.2 | 0.5 ± 0.2 | 0.8 ± 0.1 |
| DMFT | 3.9 ± 0.7 * | 0.9 ± 0.2 * | 1.1 ± 0.3 * |
Figure 1Venn diagram presents the overlap and uniqueness of differentially expressed proteins across the three comparisons. The three circles of the Venn diagram represent the three comparisons. The green circle represents the G1–G2 comparison, the blue represents the G1–Ctrl and the yellow the G2–Ctrl comparison.
Selection of biologically relevant pathways, which could be associated with caries susceptibility. The proteins highlighted in red in each path are more biologically relevant to caries pathology.
|
| ||
|
|
|
|
| Secreted | 1.79 × 10−8 | |
| GO:0042742~defense response to bacterium | IGLC7, | 1.42 × 10−6 |
| GO:0005796~Golgi lumen | 1.98 × 10−6 | |
| GO:0019825~oxygen binding | ALB, CYP1A1, HBB, HBD, HBA1 | 2.00 × 10−5 |
| signal peptide | 3.07 × 10−5 | |
| IPR006080:Beta defensin-Neutrophil defensin |
| 2.49 × 10−4 |
| Signal | 3.27 × 10−4 | |
| glycosylation site:N-linked (Glc) (glycation) | ALB, HBB, HBA1 | 3.54 × 10−4 |
| Antimicrobial | 3.84 × 10−4 | |
| Glycation | ALB, HBB, HBA1 | 4.04 × 10−4 |
| hsa04970:Salivary secretion | 0.001844339 | |
| calcium-binding region:2; high affinity | TCHH, S100P, | 0.002649627 |
| Calcium |
PCLO, | 0.003100924 |
| Pyrrolidone carboxylic acid |
| 0.004088861 |
| GO:0050832~defense response to fungus |
| 0.004847206 |
| IPR000566:Lipocalin-cytosolic fatty-acid binding protein domain | RBP4, AMBP, ORM2 | 0.006685494 |
| Defensin |
| 0.013921585 |
| GO:0004556~alpha-amylase activity |
| 0.017063442 |
| IPR006046:Alpha amylase |
| 0.0179226 |
| GO:0050829~defense response to Gram-negative bacterium | 0.019204342 | |
| IPR016327:Alpha-defensin |
| 0.021468961 |
| IPR026086:Proline-rich protein |
| 0.025002707 |
| IPR002345:Lipocalin | RBP4, AMBP | 0.028523881 |
| Glycoprotein | PSCA, AMBP, WSCD1, | 0.029468179 |
| GO:0050830~defense response to Gram-positive bacterium |
| 0.042886244 |
| Phosphoprotein | SETD2, KMT2A, SYAP1, SLC2A1, HBB, HBD, CCNDBP1, | 0.044573527 |
|
| ||
|
|
|
|
| glycosylation site:N-linked (Glc) (glycation) | ALB, HBB, | 2.20 × 10−7 |
| Glycation | ALB, HBB, | 7.69 × 10−7 |
| Pyrrolidone carboxylic acid | ORM1, | 3.33 × 10−4 |
| IPR026086:Proline-rich protein |
| 9.39 × 10−4 |
| GO:0042742~defense response to bacterium | IGHG1, IGHG2, | 0.004284705 |
| IPR002957:Keratin, type I |
| 0.021047193 |
| GO:0034190~apolipoprotein receptor binding |
| 0.021526132 |
| Antimicrobial | 0.032341013 | |
|
| ||
|
|
|
|
| Protease inhibitor |
ITIH4, APP, | 5.10 × 10−11 |
| glycosylation site:O-linked (GalNAc...) | ITIH4, HPX, TF, ITIH2, AMBP, AHSG, SERPING1, PLG | 9.29 × 10−7 |
| Glycoprotein |
APP, ITIH4, ORM1, SERPINA1, ITIH2, CFH, SERPINC1, PON1, LAMA3, SLC2A1, PLG, FURIN, A1BG, ORM2, PRH1, PKHD1, | 1.01 × 10−5 |
| GO:0006956~complement activation |
IGHG3, | 1.64 × 10−5 |
| GO:0002020~protease binding | 2.37 × 10−5 | |
| Complement alternate pathway |
| 2.99 × 10−5 |
| GO:0006953~acute-phase response | ITIH4, ORM1, SERPINA1, AHSG, ORM2 | 9.67 × 10−5 |
| GO:0045087~innate immune response | FGB, IGHG3, FGA, APP, IGHG4, C6, IGHG2, HMGB2, SERPING1, | 3.34 × 10−4 |
| Complement pathway | 5.68 × 10−4 | |
| IPR026086:Proline-rich protein |
| 6.79 × 10−4 |
| region of interest:Coil 1B |
| 6.84 × 10−4 |
| GO:0044267~cellular protein metabolic process | FGA, APP, TTR, | 8.32 × 10−4 |
| GO:0030674~protein binding, bridging | FGB, FGA, FGG, SPRR1A, OPTN | 9.68 × 10−4 |
| GO:1900026~positive regulation of substrate adhesion-dependent cell spreading | FGB, FGA, FGG, | 0.001004558 |
| glycosylation site:N-linked (Glc) (glycation) | ALB, | 0.001008382 |
| IPR001664:Intermediate filament protein |
| 0.001073524 |
| Phosphoprotein |
APP, SERPINA1, HMGB2, | 0.001509071 |
| Glycation | ALB, | 0.001739912 |
| IPR027214:Cystatin |
| 0.002464241 |
| GO:0050829~defense response to Gram-negative bacterium | APP, HMGB2, OPTN, | 0.004793789 |
| IPR003054:Type II keratin |
| 0.011288975 |
| IPR001500:Alpha-1-acid glycoprotein | ORM1, ORM2 | 0.011497863 |
Figure 2The interaction network for the G1–C comparison indicates that differentially expressed proteins have functional connections. Colored lines between the proteins indicate the various types of interaction evidence. STRING tool was used to draw the protein–protein interactions.
Selection of differentially expressed proteins involved in caries (fold change-up and down-regulation values obtained by iTRAQ). The proteins highlighted in red are more biologically relevant to caries pathology.
| Proteins | G1. vs. C. | G2. vs. C. | G1. vs. G. |
|---|---|---|---|
|
| −1.688 | −1.192 | −1.416 |
|
| −1.546 | −1.382 | −1.119 |
|
| −1.540 | −1.300 | −1.184 |
|
| −1.434 | −1.369 | −1.048 |
|
| −1.418 | 1.003 | −1.423 |
|
| −1.324 | −1.174 | −1.127 |
|
| −1.319 | 1.226 | −1.617 |
|
| −1.272 | −1.249 | −1.018 |
|
| −1.262 | −1.184 | −1.067 |
|
| −1.247 | 1.081 | −1.349 |
|
| −1.242 | −1.058 | −1.173 |
|
| −1.235 | −1.004 | −1.229 |
| CST3 | −1.222 | −1.130 | −1.081 |
|
| −1.222 | 1.174 | −1.435 |
| CST5 | −1.209 | −1.008 | −1.199 |
| KRT9 | −1.204 | −1.165 | −1.034 |
|
| −1.201 | 1.057 | −1.269 |
| APOA1 | −1.198 | 1.247 | −1.496 |
| MUC7 | −1.188 | −1.236 | 1.040 |
| SERPINC1 | −1.166 | 1.058 | −1.235 |
|
| −1.162 | 1.046 | −1.216 |
|
| −1.149 | 1.053 | −1.211 |
|
| −1.135 | 1.111 | −1.261 |
|
| −1.120 | 1.074 | −1.202 |
|
| −1.118 | 1.104 | −1.235 |
|
| −1.087 | 1.099 | −1.196 |
|
| 1.147 | −1.025 | 1.175 |
|
| 1.223 | 1.010 | 1.211 |
|
| 1.224 | 1.113 | 1.100 |
|
| 1.228 | 1.223 | 1.004 |
|
| 1.255 | 1.049 | 1.197 |
|
| 1.337 | 1.000 | 1.337 |
| ATP11B | 1.471 | 1.046 | 1.406 |
|
| 1.497 | −1.256 | 1.880 |
|
| −1.261 | 1.120 | −1.412 |
|
| −1.268 | 1.169 | −1.482 |
Figure 3Selection of differentially expressed proteins among the three comparisons. The y axis refers to log2ratio values.
Figure 4LC-MRM analysis was performed to validate selected proteins across the three comparisons. The y axis refers to log2ratio values.